Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Giovanni Palladini, MD PhD, Paolo Milani, MDPhD, Simone Celant, Valentina Summa, MD, Giovanni Affronti, Pier Paolo Olimpieri, PhD, Sandra Petraglia, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Giampaolo Merlini, MD, Pierluigi Russo, MD PhD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-141563

Published: 2020

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

Journal Articles

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Paolo Milani, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2018-99-118108

Published: 2018

Journal Articles

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Giovanni Palladini, MDPhD, Ute Hegenbart, Paolo Milani, MD, Marco Basset, MD, Christoph Kimmich, MD, Francesca Russo, MD, Tilman Bochtler, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Stefan Schönland, MD

Blood (2017) 130 (Supplement 1): 1759.

https://doi.org/10.1182/blood.V130.Suppl_1.1759.1759

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Giovanni Palladini, MDPhD, Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 4346.

https://doi.org/10.1182/blood.V130.Suppl_1.4346.4346

Published: 2017

Journal Articles

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Giovanni Palladini, MD PhD, Margherita Massa, Marco Basset, MD, Francesca Russo, MD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 3261.

https://doi.org/10.1182/blood.V128.22.3261.3261

Published: 2016

Journal Articles

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 2140.

https://doi.org/10.1182/blood.V128.22.2140.2140

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients

Giovanni Palladini, MD PhD, Paolo Milani, MD, Eloisa Riva, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2015) 126 (23): 190.

https://doi.org/10.1182/blood.V126.23.190.190

Published: 2015

Journal Articles

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Paolo Milani, MD, Andrea Foli, MD, Marco Basset, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2015) 126 (23): 1773.

https://doi.org/10.1182/blood.V126.23.1773.1773

Published: 2015

Journal Articles

Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome

Giovanni Palladini, MD PhD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2014) 124 (21): 3361.

https://doi.org/10.1182/blood.V124.21.3361.3361

Published: 2014

Journal Articles

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis

Giovanni Palladini, MD PhD, Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Paolo Milani, MD, Julian D Gillmore, Andrea Foli, MD, Philip N Hawkins, Giampaolo Merlini, MD, Ashutosh D Wechalekar

Blood (2014) 124 (21): 305.

https://doi.org/10.1182/blood.V124.21.305.305

Published: 2014

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2014) 124 (21): 35.

https://doi.org/10.1182/blood.V124.21.35.35

Published: 2014

Journal Articles

First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant

Giovanni Palladini, MD, PhD, Paolo Milani, MD, Marta Vidus Rosin, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2013) 122 (21): 1985.

https://doi.org/10.1182/blood.V122.21.1985.1985

Published: 2013

Journal Articles

Identification Of Reversible Organ Damage and Of Early Markers Of Response To Treatment In Renal AL Amyloidosis: A Study On 461 Patients

Giovanni Palladini, MD, PhD, Paolo Milani, MD, Marta Vidus Rosin, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2013) 122 (21): 3087.

https://doi.org/10.1182/blood.V122.21.3087.3087

Published: 2013

NARROW

The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients

Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome

A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant

Identification Of Reversible Organ Damage and Of Early Markers Of Response To Treatment In Renal AL Amyloidosis: A Study On 461 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only